Compare BridgeBio Pharma Inc (BBIO) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Expedia Group Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Expedia Group Inc trades at $321.16 (market cap $37.69B). The key difference: Expedia Group Inc is far larger — about 2.3× BridgeBio Pharma Inc's market cap, and Expedia Group Inc pays a 0.61% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | EXPE | |
|---|---|---|
Market Cap | $16.61B | $37.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $319.66 |
52-Week Low | $47.29 | $188.51 |
Enterprise Value | $18.16B | $36.25B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Expedia Group (EXPE) trades at $310.68, up 1.34% on the day, with a bullish technical signal supported by moving averages and strong quarterly earnings beats. The company reported Q2 2026 EPS of $5.76, exceeding expectations, driven by 14% revenue growth and robust B2B performance. Valuation metrics include a P/E of 19.54 and P/S of 2.51, with net income margin improving to 12.97% in 2025. Recent news highlights AI integration and raised full-year guidance, reflecting operational strength.
The outlook for EXPE is positive, with earnings momentum and strategic expansions offering upside potential, though high debt levels and travel industry volatility pose risks. Analysts project a consensus price target of $322.95, with 47% buy ratings, indicating cautious optimism. Investors should weigh solid fundamentals against macroeconomic sensitivities affecting travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
